4432. Multiple Cerebral Hemorrhages in a Patient Receiving Lecanemab and Treated with t-PA for Stroke.
作者: Nicholas J Reish.;Pouya Jamshidi.;Brian Stamm.;Margaret E Flanagan.;Elizabeth Sugg.;Mengxuan Tang.;Kelly L Donohue.;Matthew McCord.;Chase Krumpelman.;Marek-Marsel Mesulam.;Rudolph Castellani.;Sherry H-Y Chou.
来源: N Engl J Med. 2023年388卷5期478-479页 4436. Drug Sensitivity of Currently Circulating Mpox Viruses.
作者: Denisa Bojkova.;Marco Bechtel.;Tamara Rothenburger.;Katja Steinhorst.;Nadja Zöller.;Stefan Kippenberger.;Julia Schneider.;Victor M Corman.;Hannah Uri.;Mark N Wass.;Gaby Knecht.;Pavel Khaykin.;Timo Wolf.;Sandra Ciesek.;Holger F Rabenau.;Martin Michaelis.;Jindrich Cinatl.
来源: N Engl J Med. 2023年388卷3期279-281页 4437. VV116 versus Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19.
作者: Zhujun Cao.;Weiyi Gao.;Hong Bao.;Haiyan Feng.;Shuya Mei.;Peizhan Chen.;Yueqiu Gao.;Zhilei Cui.;Qin Zhang.;Xianmin Meng.;Honglian Gui.;Weijing Wang.;Yimei Jiang.;Zijia Song.;Yiqing Shi.;Jing Sun.;Yifei Zhang.;Qing Xie.;Yiping Xu.;Guang Ning.;Yuan Gao.;Ren Zhao.
来源: N Engl J Med. 2023年388卷5期406-417页
Nirmatrelvir-ritonavir has been authorized for emergency use by many countries for the treatment of coronavirus disease 2019 (Covid-19). However, the supply falls short of the global demand, which creates a need for more options. VV116 is an oral antiviral agent with potent activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
4440. Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster.
作者: Meredith E Davis-Gardner.;Lilin Lai.;Bushra Wali.;Hady Samaha.;Daniel Solis.;Matthew Lee.;Andrea Porter-Morrison.;Ian T Hentenaar.;Fumiko Yamamoto.;Sucheta Godbole.;Yuan Liu.;Daniel C Douek.;Frances Eun-Hyung Lee.;Nadine Rouphael.;Alberto Moreno.;Benjamin A Pinsky.;Mehul S Suthar.
来源: N Engl J Med. 2023年388卷2期183-185页 |